APA (7th ed.) Citation

Fang, Y., Su, N., Zou, Q., Cao, Y., Xia, Y., Tang, L., . . . Cai, Q. (2023). Anlotinib as a third-line or further treatment for recurrent or metastatic nasopharyngeal carcinoma: A single-arm, phase 2 clinical trial. BMC Medicine, 21(1), 1. https://doi.org/10.1186/s12916-023-03140-x

Chicago Style (17th ed.) Citation

Fang, Yu, Ning Su, Qihua Zou, Yi Cao, Yi Xia, Linquan Tang, Xiaopeng Tian, Panpan Liu, and Qingqing Cai. "Anlotinib as a Third-line or Further Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Single-arm, Phase 2 Clinical Trial." BMC Medicine 21, no. 1 (2023): 1. https://doi.org/10.1186/s12916-023-03140-x.

MLA (9th ed.) Citation

Fang, Yu, et al. "Anlotinib as a Third-line or Further Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Single-arm, Phase 2 Clinical Trial." BMC Medicine, vol. 21, no. 1, 2023, p. 1, https://doi.org/10.1186/s12916-023-03140-x.